First subject dosed in psilocybin trial for rare headache disorderThe first patient has received a low dose of Beckley Psytech’s psychedelic medicine psilocybin in a clinical trial Share XFirst subject dosed in psilocybin trial for rare headache disorderhttps://pharmaphorum.com/news/first-subject-dosed-in-psilocybin-trial-for-rare-headache-disorder/
AbbVie spies potential in Regenxbio eye disease gene therapyAbbVie has expanded its ophthalmology pipeline via a licensing deal with Regenxbio, paying $370 million upfront to get Share XAbbVie spies potential in Regenxbio eye disease gene therapyhttps://pharmaphorum.com/news/abbvie-spies-potential-in-regenxbio-eye-disease-gene-therapy/
Apellis reports mixed data with eye drug, but plans to file anywayApellis Pharma has reported mixed results with its lead drug pegcetacoplan in geographic atrophy (GA) – a major Share XApellis reports mixed data with eye drug, but plans to file anywayhttps://pharmaphorum.com/news/apellis-reports-mixed-data-with-eye-drug-but-plans-to-file-anyway/
Server cans autism hope bumetanide after phase 3 failsServier and Neurochlore have been forced to admit defeat in their bid to bring the first drug to Share XServer cans autism hope bumetanide after phase 3 failshttps://pharmaphorum.com/news/server-cans-autism-hope-bumetanide-after-phase-3-fails/
Hybrigenics says it wants a merger with Bone TherapeuticsFrench biopharma company Hybrigenics has made another bid to merge with Belgium’s Bone Therapeutics, a specialist in regenerative Share XHybrigenics says it wants a merger with Bone Therapeuticshttps://pharmaphorum.com/news/hybrigenics-says-it-wants-a-merger-with-bone-therapeutics/
Bayer’s eliapixant hits the right notes in PAGANINI cough studyBayer has released the data in its phase 2b trial of eliapixant in refractory chronic cough, as it Share XBayer’s eliapixant hits the right notes in PAGANINI cough studyhttps://pharmaphorum.com/news/bayers-eliapixant-hits-the-right-notes-in-paganini-cough-study/
FDA slaps clinical hold on BioMarin’s PKU gene therapyBioMarin Pharma has had another setback in its gene therapy development programme, announcing this morning that the FDA Share XFDA slaps clinical hold on BioMarin’s PKU gene therapyhttps://pharmaphorum.com/news/fda-slaps-clinical-hold-on-biomarins-pku-gene-therapy/
Amgen builds case for severe asthma drug tezepelumabAmgen and partner AstraZeneca have said their recently filed severe asthma drug tezepelumab has shown impressive results in Share XAmgen builds case for severe asthma drug tezepelumabhttps://pharmaphorum.com/news/amgen-builds-case-for-severe-asthma-drug-tezepelumab/
Novartis’ transplant drug hope iscalimab flunks mid-stage trialNovartis hopes of improving on tacrolimus as the standard drug for preventing organ rejection in transplant patients have Share XNovartis’ transplant drug hope iscalimab flunks mid-stage trialhttps://pharmaphorum.com/news/novartis-transplant-drug-hope-iscalimab-flunks-mid-stage-trial/
Pfizer raises pressure on GSK, J&J with late-stage RSV vaccine trialPfizer has vaulted ahead with its respiratory syncytial virus (RSV) vaccine, closing the gap with GlaxoSmithKline and Johnson Share XPfizer raises pressure on GSK, J&J with late-stage RSV vaccine trialhttps://pharmaphorum.com/news/pfizer-raises-pressure-on-gsk-jj-with-late-stage-rsv-vaccine-trial/
J&J vaccine fails to protect women against HIV infectionJohnson & Johnson’s HIV vaccine candidate has failed its first major efficacy test, as it was unable to Share XJ&J vaccine fails to protect women against HIV infectionhttps://pharmaphorum.com/news/jj-vaccine-fails-to-protect-women-against-hiv-infection/
AC Immune claims half a win for tau drug in Alzheimer’s trialShares in AC Immune leaped today after the company said its tau-targeting Alzheimer’s disease candidate semorinemab hit one Share XAC Immune claims half a win for tau drug in Alzheimer’s trialhttps://pharmaphorum.com/news/ac-immune-claims-half-a-win-for-tau-drug-in-alzheimers-trial/
‘Endless RNA’ startup Laronde raises $440m to fuel pipelineJust a few months after breaking cover with its new take on RNA therapeutics, Laronde has raised an Share X‘Endless RNA’ startup Laronde raises $440m to fuel pipelinehttps://pharmaphorum.com/news/endless-rna-startup-laronde-raises-440m-to-fuel-pipeline/
GSK takes SK bio-partnered COVID jab into phase 3As a top vaccine maker, GlaxoSmithKline has been a laggard in the COVID-19 vaccine race, but has put Share XGSK takes SK bio-partnered COVID jab into phase 3https://pharmaphorum.com/news/gsk-takes-sk-bio-partnered-covid-jab-into-phase-3/
Data points to big win for Jardiance in hard-to-treat heart failureThe data is now in from the EMPEROR-Preserved study of Boehringer Ingelheim and Eli Lilly’s Jardiance in heart Share XData points to big win for Jardiance in hard-to-treat heart failurehttps://pharmaphorum.com/news/data-points-to-big-win-for-jardiance-in-hard-to-treat-heart-failure/
After Ultomiris stumble, Alexion delivers a rare disease win for AZA drug for Wilson disease developed by AstraZeneca’s Alexion rare disease unit has cleared a phase 3 trial, Share XAfter Ultomiris stumble, Alexion delivers a rare disease win for AZhttps://pharmaphorum.com/news/after-ultomiris-stumble-alexion-delivers-a-rare-disease-win-for-az/
Merck & Co raises pressure on Pfizer in pneumococcal vaccine tussleJust a month after getting approval for its new pneumococcal vaccine Vaxneuvance in adults, Merck & Co has Share XMerck & Co raises pressure on Pfizer in pneumococcal vaccine tusslehttps://pharmaphorum.com/news/merck-raises-pressure-on-pfizer-in-pneumococcal-vaccine-tussle/
Lilly taps Lycia for protein degrader tech in $1.6bn dealEli Lilly has bolstered its position the fast-emerging area of protein degrader drugs, agreeing a $1.6 billion-plus deal Share XLilly taps Lycia for protein degrader tech in $1.6bn dealhttps://pharmaphorum.com/news/lilly-taps-lycia-for-protein-degrader-tech-in-1-6bn-deal/
